Patent describes construction of specific mutant of Streptomyces hygroscopicus which was used to generate novel rapamycin analogues using precursor-directed biosynthesis (Technology was licenced to pharmaceutical company Wyeth). Patent is now granted in Europe (EP1589031) and USA (US7300942). Some of the expertise acquired during the preparation of this patent, was used during the execution of this project.
F.32 International patent
COBISS.SI-ID: 3622008In collaboration with pharmaceutical company Krka, we have developed a new and patent-independent fermentation process for production of generic product from group of secondary metabolites. PCT patent application was filed. Some of the expertise acquired during this research project has contributed to the creation of this patent application.
F.09 Development of a new technological process or technology
COBISS.SI-ID: 3393144Publication includes articles of Slovene research groups and companies in the field of antibiotics. Presentation and publication presents extensive work of Slovene academic and industrial institutions from field of production of microbial and plant antimicrobial agents, applied in pharmacy, food production and medicine, mechanisms of their action, regulation of their biosynthesis, their isolation and occurrence of resistance
C.02 Editorial board of a national monograph
COBISS.SI-ID: 243594496Lecture on scientific meeting where new biosynthetic engineering approaches were presented for preparation of novelpolyketide compounds, which possess a wealth of pharmacological effects, including antibacterial, antifungal, antiparasitic, anticancer and immunosuppressive activities. Many of these compounds and their semi-synthetic derivatives are used today in the clinic. Recent advances in the area of biosynthetic engineering of the enzymes involved in polyketide biosynthesis are presented in this review
B.04 Guest lecture
COBISS.SI-ID: 3577976Chelocardin is a polyketide from the group of tetracyclins. We have cloned and sequenced its biosynthetic gene cluster which was previously unknown and patented the invention. The patent protects the rights to exploit the chelocardin gene cluster for novel chelocardin analogues design using the biosynthetical and semisynthetical chemical approaches and was filed at the European Patent Office (EPO) and United States Patent and Trademark Office (USPTO). Some of the expertise acquired during the preparation of this patent, was used during the execution of this project.
F.32 International patent
COBISS.SI-ID: 3689080